drugset / Trial / NCT02265653
Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
The objective of the present study is to investigate the relative bioavailability of two BIIL 284 BS tablets (tablet C and tablet C) in comparison to the WIF tablet at a dose of 75 mg following a standard breakfast in healthy male volunteers
Timeline
- Start
- 1999-11
- Primary completion
- 1999-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMELUBANT | Small molecule | 75 mg | — |
Indications
No indication recorded.